Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Gotistobart by OncoC4 for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Gotistobart is under clinical development by OncoC4 and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
Data Insights
Risk adjusted net present value: What is the current valuation of BioNTech's Gotistobart?
Gotistobart is a monoclonal antibody commercialized by BioNTech, with a leading Phase II program in Adenoid Cystic Carcinoma (ACC). According...